COVID-19 vaccination in mainland China
Date | 22 July 2020 | – present
---|---|
Location | China |
Cause | COVID-19 pandemic in China |
Target | Immunization against COVID-19 |
Organized by | Joint Prevention and Control Mechanism in Response to the COVID-19 pandemic, State Council (headquartered at National Health Commission) |
Participants | 1,049,744 thousand total doses administered (as of 21 June 2021)[DR 1] |
Outcome | ~30% of the total population has received at least one dose. (as of 23 May 2021)[1] |
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
COVID-19 vaccination in mainland China is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Mainland China, in response to the ongoing pandemic in the region.
Administration[edit]
On December 19, 2020, the National Health Commission (NHC) said that there has been 1 million doses of COVID-19 vaccine administered in Chinese Mainland as of the day, and no serious adverse reactions were observed.[2]
On January 27, 2021, the National Health Commission said that the vaccination is being carried out in order, and there has been 22.767 million doses of COVID-19 vaccine administered in Chinese Mainland as of January 26.[3]
On March 1, 2021, Zhong Nanshan said that the vaccination rate of COVID-19 vaccine in China was currently 3.56%, and the Chinese Center for Disease Control and Prevention hoped the rate reach 40% by the end of June 2021.[4]
On March 24, 2021, NHC announced that the number doses of COVID-19 vaccine administered will be daily reported on its website and social media account since that day.[5]
On April 21, 2021, NHC stated that more that 200 million doses of COVID-19 vaccine has been administered in Chinese Mainland, and 80% of doctors and nurses has been administered.[6]
On May 14, 2021, NHC restated that the COVID-19 administration progress should be accelerated due to the proportion of mutated SARS-CoV-2 and the re-appearance of local cases.[7]
On June 19, 2021, NHC announced that more than 1.01489 billion doses of COVID-19 vaccine has been administered in Chinese Mainland.[8]
As of | Doses administrated (in million) |
Notes | References |
---|---|---|---|
Dec 19 (2020) |
>1 | [2] | |
Jan 27 (2021) |
22.76 | [3] | |
Feb 9 | 40.52 | [9] | |
Mar 15 | 64.98 | [10] | |
Mar 28 | 102.417 | 100 million doses administered | [DR 2] |
Apr 21 | 204.191 | 200 million doses administered | [DR 3] |
May 7 | 308.226 | 300 million doses administered | [DR 4] |
May 16 | 406.938 | 400 million doses administered | [DR 5] |
May 23 | 510.858 | 500 million doses administered | [DR 6] |
May 28 | 602.991 | 600 million doses administered | [DR 7] |
Jun 2 | 704.826 | 700 million doses administered | [DR 8] |
Jun 8 | 808.962 | 800 million doses administered | [DR 9] |
Jun 14 | 904.134 | 900 million doses administered | [DR 10] |
Jun 19 | 1,010.489 | 1 billion doses administered | [DR 11] |
Vaccines[edit]
As of June 10, 2021, seven vaccines have been approved in China through conditional marketing authorization or emergency use authorization.
Vaccine | Type | Made by | Origin | Dose required for vaccination | Effective rate (Phase III) | Approval | Deployment | WHO Listed |
---|---|---|---|---|---|---|---|---|
BBIBP-CorV | Inactived | Beijing Institute of Biological Products | China | 2 doses[11] | 86%[12] | Conditional (December 31, 2020)[13] |
December 31, 2020 | May 7, 2021 |
CoronaVac | Inactived | Sinovac Biotech | China | 2 doses[11] | 50.4% - 83.5%[14][15][16] | Conditional (February 5, 2021)[17] |
February 5, 2021 | June 1, 2021 |
WIBP-CorV | Inactived | Wuhan Institute of Biological Products | China | 2 doses[11] | 72.8%[18] | Conditional (February 25, 2021)[19] |
February 25, 2021 | |
Keweike | Inactived | Kangtai Biological Products Co. Ltd. | China | 2 doses[11] | N/A | EUA (May 14, 2021)[20] |
June 1, 2021 | |
Keweifu | Inactived | Institute of Medical Biology, Chinese Academy of Medical Sciences | China | 2 doses[11] | N/A | EUA (June 9, 2021)[21] |
June 9, 2021 | |
Convidecia | Viral vector | CanSino | China | 1 dose[11] | 65.7%[22] | Conditional (February 25, 2021)[23] |
February 25, 2021 | |
ZIFIVAX | Subunit (CHO) | Zhifei Bio-tech | China | 3 doses[11] | ~97%[24] | EUA (March 10, 2021)[25] |
March 10, 2021 |
References[edit]
Daily reports on COVID-19 vaccination[edit]
- ^ National health and Health Commission (22 June 2021). "新冠病毒疫苗接种情况".
- ^ National health and Health Commission (29 March 2021). "新冠病毒疫苗接种情况".
- ^ National health and Health Commission (22 April 2021). "新冠病毒疫苗接种情况".
- ^ National health and Health Commission (8 May 2021). "新冠病毒疫苗接种情况".
- ^ National health and Health Commission (17 May 2021). "新冠病毒疫苗接种情况".
- ^ National health and Health Commission (24 May 2021). "新冠病毒疫苗接种情况".
- ^ National health and Health Commission (29 May 2021). "新冠病毒疫苗接种情况".
- ^ National health and Health Commission (3 June 2021). "新冠病毒疫苗接种情况".
- ^ National health and Health Commission (9 June 2021). "新冠病毒疫苗接种情况".
- ^ National health and Health Commission (15 June 2021). "新冠病毒疫苗接种情况".
- ^ National health and Health Commission (20 June 2021). "新冠病毒疫苗接种情况".
News and Articles[edit]
- ^ Wu, Bin (24 May 2021). "累计接种破5亿剂次,中国离群体免疫还有多远?". Southern Metropolis Daily. Retrieved 19 June 2021.
- ^ a b "目前累计已完成100多万剂次新冠疫苗紧急接种 未出现严重不良反应". SCIO. 19 December 2020. Retrieved 2 April 2021.
- ^ a b 彭韵佳 王琳琳 (27 January 2021). "目前我国已接种新冠疫苗2276.7万剂次". Xinhua News Agency.
- ^ "钟南山:中国疫苗接种率为3.56%,计划6月底达40%". Guancha.cn. Retrieved 16 March 2021.
- ^ "中国今起开始日报冠病疫苗接种数量". Lianhe Zaobao. 24 March 2021. Retrieved 25 March 2021.
- ^ "全国新冠疫苗接种超2亿剂次". Chinanews.com. Retrieved 23 April 2021.
- ^ "国家卫健委:5月至今新增境外输入确诊病例142例 必须加快推进新冠疫苗接种". People.com.cn. 14 May 2021. Retrieved 14 May 2021.
- ^ "权威快报|全国新冠疫苗接种剂次超10亿". Xinhuanet.com. Xinhua News Agency. 20 June 2021.
- ^ 张曼玉 (10 February 2021). "全国累计报告接种新冠疫苗4052万剂次,现有本土确诊病例连续15天下降". China Youth Daily.
- ^ 彭韵佳 王琳琳 (15 March 2021). "我国新冠疫苗接种已达6498万人次". Xinhua News Agency.
- ^ a b c d e f g "新冠病毒疫苗接种问答来了!涉及34个关键问题". Chinanews.com. 1 April 2021. Retrieved 2 April 2021.
- ^ "National Health Regulatory Authority approves Sinopharm COVID-19 vaccine". BNA. 13 December 2020. Archived from the original on 14 February 2021. Retrieved 14 February 2021.
- ^ "大陸宣布首款新冠疫苗有條件上市 保護率近八成". UDN (in Chinese). 31 December 2020. Retrieved 31 December 2020.
- ^ "Sinovac: Brazil results show Chinese vaccine 50.4% effective". BBC News. 13 January 2021. Archived from the original on 10 March 2021. Retrieved 13 March 2021.
- ^ "Turkey set to receive 'effective' COVID-19 vaccine amid calls for inoculation". Daily Sabah. 25 December 2020. Archived from the original on 8 January 2021. Retrieved 13 March 2021.
- ^ "Indonesia grants emergency use approval to Sinovac's vaccine, local trials show 65% efficacy". The Straits Times. 11 January 2021. Archived from the original on 30 January 2021. Retrieved 13 March 2021.
- ^ "China approves Sinovac vaccines for general public use". South China Morning Post. 6 February 2021. Retrieved 23 June 2021.
- ^ Al Kaabi, Nawal; Zhang, Yuntao; Xia, Shengli; Yang, Yunkai; Al Qahtani, Manaf M.; Abdulrazzaq, Najiba; Al Nusair, Majed; Hassany, Mohamed; Jawad, Jaleela S. (26 May 2021). "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial". JAMA. doi:10.1001/jama.2021.8565. ISSN 0098-7484.
- ^ "国家药监局附条件批准国药中生武汉公司新型冠状病毒灭活疫苗(Vero细胞)注册申请". National Medical Products Administration. 25 February 2021. Retrieved 25 February 2021.
- ^ "深圳康泰生物新冠灭活疫苗被纳入紧急使用". Xinhuanet.com. 15 May 2021. Retrieved 15 May 2021.
- ^ UDN (9 June 2021). "中國大陸再有一新冠病毒滅活疫苗上市使用". UDN (in Chinese). Retrieved 10 June 2021.
- ^ "CanSinoBIO's COVID-19 vaccine 65.7% effective in global trials, Pakistan official says". Reuters. 8 February 2021. Retrieved 8 February 2021.
- ^ "中国国家药监局附条件批准国药集团武汉和康希诺两公司新冠疫苗注册申请".
- ^ "智飞生物冠病疫苗临床结果显示有效率达97%". Lianhe Zaobao (in Chinese). 26 March 2021. Retrieved 3 April 2021.
- ^ "新冠疫苗|智飛生物與中科院微生物所合作研發產品獲批緊急使用". HK01 (in Chinese). 16 March 2021. Retrieved 3 April 2021.